DSDaniel J. Smith

Daniel J. Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel J. Smith has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring Longterm Gastrostomy Use in Adults With Cystic Fibrosis

    by Felicity Loel, Tracy McMahon, Angela G. Matson, Shanal Kumar, Daniel Smith

    Introduction: Gastrostomies are used to support nutritional adequacy, growth and lung function in people with Cystic Fibrosis (CF). Adults with CF living with a gastrostomy face unique challenges due to the time and length of placement often being inserted in childhood and extending through to adulthood. In the era of CF modulator therapies removal of gastrostomies is increasingly being contemplated, and our aim was to understand experiences and perspectives of adults with CF who have lived with a gastrostomy. Methods: This was a single‐centre qualitative study in adults with CF who have lived with a gastrostomy. All semi‐structured interviews were audio recorded, transcribed and analyzed inductively using grounded theory methodology. Data saturation was reached when no new codes emerged. Findings were summarized into major conceptual themes. Participant demographics and medical history were obtained. Results: In total, thirteen participants completed semi‐structured interviews. Analyzes revealed four main themes in adults with CF who have lived with a gastrostomy (1) Psychological (i.e. body image, embarrassment, isolating/social stigma, acceptance/adjustment), (2) Pain & physical concerns (i.e. general pain, hyper granulation, leaking), (3) Social (i.e. relationships and navigating social conversations), and (4) Functionality. Conclusion: Our study explored lived experiences of adults with CF and a gastrostomy. We found there was significant psychological and social impact of growing up with a gastrostomy, highlighting the need for clinicians to provide holistic support that addresses both physical and mental challenges of long‐term gastrostomy care for adults with CF.

  • Open Access

    Treatment of Pseudomonas by Removal of Cloaking Antibodies: Is Common Polysaccharide Antigen a Factor?

    by Joshua N Monteith, Emma L Ledger, Michelle N Chamoun, Ian R Henderson, Joanna B Goldberg, Daniel Smith, Daniel C Chambers, Simon H Apte, Timothy J Wells

    Background: People with cystic fibrosis (pwCF) are susceptible to chronic lung infections, particularly with Pseudomonas aeruginosa. During infection, a subset of patients develops cloaking antibodies specific to O-antigen lipopolysaccharide that impair complement-mediated bactericidal killing. These antibodies associate with worse disease, and their removal via plasmapheresis has been used as a successful treatment for multidrug-resistant P aeruginosa. Whether a similar mechanism of antibody-mediated serum resistance exists toward common polysaccharide antigen (CPA) lipopolysaccharide is unknown. Methods: Forty-two serum samples and 63 matched P aeruginosa isolates were collected from pwCF. The titers of antibodies specific to CPA in patient sera were determined, and the ability of these antibodies to inhibit serum-mediated killing of P aeruginosa was assessed. Results: Despite widespread anti-CPA antibodies, only 1 serum-strain pair showed evidence of complement inhibition. Patient serum IgG and IgA responses to CPA were elevated in 86% and 69% of sera, respectively. Furthermore, 69% of pwCF were colonized with CPA-expressing isolates. Despite the high prevalence of elevated anti-CPA antibodies, only 1 patient had antibodies capable of inhibiting complement killing of the cognate P aeruginosa. This isolate, CFP3A, had significantly higher expression of CPA than all other strains. Complement-mediated killing toward it was inhibited by anti-CPA antibodies in a titer-dependent manner. Conclusions: This investigation reveals that although antibody specific for CPA is prevalent in pwCF, it cannot inhibit complement killing of the majority of CPA-expressing strains. Thus, when Pseudomonas is treated by removal of cloaking antibodies, it is unlikely that CPA-specific antibodies will also need to be eliminated.


  • Top Cited Papers
    Open Access

    The Influence of Wearables on Health Care Outcomes in Chronic Disease: Systematic Review

    by Graeme Mattison, Oliver Canfell, Doug Forrester, Chelsea Dobbins, Daniel Smith, Juha Töyräs, Clair Sullivan

    Background: Chronic diseases contribute to high rates of disability and mortality. Patient engagement in chronic disease self-management is an essential component of chronic disease models of health care. Wearables provide patient-centered health data in real time, which can help inform self-management decision-making. Despite the perceived benefits of wearables in improving chronic disease self-management, their influence on health care outcomes remains poorly understood. Objective: This review aimed to examine the influence of wearables on health care outcomes in individuals with chronic diseases through a systematic review of the literature. Methods: A narrative systematic review was conducted by searching 6 databases for randomized and observational studies published between January 1, 2016, and July 1, 2021, that included the use of a wearable intervention in a chronic disease group to assess its impact on a predefined outcome measure. These outcomes were defined as any influence on the patient or clinician experience, cost-effectiveness, or health care outcomes as a result of the wearable intervention. Data from the included studies were extracted based on 6 key themes, which formed the basis for a narrative qualitative synthesis. All outcomes were mapped against each component of the Quadruple Aim of health care. The guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement were followed in this study. Results: A total of 30 articles were included; studies reported 2446 participants (mean age: range 10.1-74.4 years), and the influence of 14 types of wearables on 18 chronic diseases was presented. The most studied chronic diseases were type 2 diabetes (4/30, 13%), Parkinson disease (3/30, 10%), and chronic lower back pain (3/30, 10%). The results were mixed when assessing the impact on a predefined primary outcome, with 50% (15/30) of studies finding a positive influence on the studied outcome and 50% (15/30) demonstrating a nil effect. There was a positive effect of 3D virtual reality systems on chronic pain in 7% (2/30) of studies that evaluated 2 distinct chronic pain syndromes. Mixed results were observed in influencing exercise capacity; weight; and biomarkers of disease, such as hemoglobin A1c, in diabetes. In total, 155 outcomes were studied. Most (139/155, 89.7%) addressed the health care outcomes component. This included pain (11/155, 7.5%), quality of life (7/155, 4.8%), and physical function (5/155, 3.4%). Approximately 7.7% (12/155) of outcome measures represented the patient experience component, with 1.3% (2/155) addressing the clinician experience and cost. Conclusions: Given their popularity and capability, wearables may play an integral role in chronic disease management. However, further research is required to generate a strong evidence base for safe and effective implementation. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42021244562; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=244562


  • Open Access

    The Influence of Wearables on Health Care Outcomes in Chronic Disease: Systematic Review (Preprint)

    by Graeme Mattison, Oliver Canfell, Doug Forrester, Chelsea Dobbins, Daniel Smith, Juha Töyräs, Clair Sullivan

    BACKGROUND Chronic diseases contribute to high rates of disability and mortality. Patient engagement in chronic disease self-management is an essential component of chronic disease models of health care. Wearables provide patient-centered health data in real time, which can help inform self-management decision-making. Despite the perceived benefits of wearables in improving chronic disease self-management, their influence on health care outcomes remains poorly understood. OBJECTIVE This review aimed to examine the influence of wearables on health care outcomes in individuals with chronic diseases through a systematic review of the literature. METHODS A narrative systematic review was conducted by searching 6 databases for randomized and observational studies published between January 1, 2016, and July 1, 2021, that included the use of a wearable intervention in a chronic disease group to assess its impact on a predefined outcome measure. These outcomes were defined as any influence on the patient or clinician experience, cost-effectiveness, or health care outcomes as a result of the wearable intervention. Data from the included studies were extracted based on 6 key themes, which formed the basis for a narrative qualitative synthesis. All outcomes were mapped against each component of the Quadruple Aim of health care. The guidelines of the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement were followed in this study. RESULTS A total of 30 articles were included; studies reported 2446 participants (mean age: range 10.1-74.4 years), and the influence of 14 types of wearables on 18 chronic diseases was presented. The most studied chronic diseases were type 2 diabetes (4/30, 13%), Parkinson disease (3/30, 10%), and chronic lower back pain (3/30, 10%). The results were mixed when assessing the impact on a predefined primary outcome, with 50% (15/30) of studies finding a positive influence on the studied outcome and 50% (15/30) demonstrating a nil effect. There was a positive effect of 3D virtual reality systems on chronic pain in 7% (2/30) of studies that evaluated 2 distinct chronic pain syndromes. Mixed results were observed in influencing exercise capacity; weight; and biomarkers of disease, such as hemoglobin A1c, in diabetes. In total, 155 outcomes were studied. Most (139/155, 89.7%) addressed the health care outcomes component. This included pain (11/155, 7.5%), quality of life (7/155, 4.8%), and physical function (5/155, 3.4%). Approximately 7.7% (12/155) of outcome measures represented the patient experience component, with 1.3% (2/155) addressing the clinician experience and cost. CONCLUSIONS Given their popularity and capability, wearables may play an integral role in chronic disease management. However, further research is required to generate a strong evidence base for safe and effective implementation. CLINICALTRIAL PROSPERO International Prospective Register of Systematic Reviews CRD42021244562; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=244562

  • Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV1) in cystic fibrosis patients receiving ivacaftor treatment

    by Béla Nagy, Zsolt Bene, Zsolt Fejes, Sonya L. Heltshe, David Reid, Nicola J. Ronan, Yvonne McCarthy, Daniel Smith, Attila Nagy, Elizabeth Joseloff, et al.


  • Increased physical activity post-exacerbation is associated with decreased systemic inflammation in cystic fibrosis – An observational study

    by Kate Burton, Norman R. Morris, David Reid, Daniel Smith, Suzanne Kuys

    Background and Objective: We assessed whether measured physical activity in adults with cystic fibrosis (CF) following in-hospital treatment for an acute exacerbation was impacted by levels of systemic and airway inflammation, and whether physical activity post-discharge predicted for time to next pulmonary exacerbation. Methods: Adults with CF were included following hospitalization for a pulmonary exacerbation, and were followed for 12 months. Inflammatory markers and physical activity were measured immediately post-discharge via sputum and plasma concentrations of interleukin-6, interleukin-8, and tumor necrosis factor-α. Physical activity was monitored for 7 days via a Sensewear Armband. Statistical analyses included Shapiro-Wilk’s test and Q–Q plots to determine normal distribution, t-tests, Pearson’s correlational analyses, and one-way MANOVAs. Results: Thirty-one adults with CF (13 females, 28.8 ± 8.8 years, forced expiratory volume in 1 s (FEV1) 59.4 ± 23.0% predicted) were prospectively recruited. Physical activity negatively correlated with plasma inflammation (r = −0.48, p < 0.01), and positively with FEV1 (r = 0.45, p < 0.05) and body mass index (r = 0.39, p < 0.05). There was no significant relationship between time to re-exacerbation and any inflammatory markers or measurement of physical activity (all p > 0.05). Conclusion: Increased physical activity following exacerbation in CF is associated with lower levels of systemic inflammation. Time to re-exacerbation is not related to post-discharge inflammation or physical activity levels.


  • Mutations in the HFE gene can be associated with increased lung disease severity in cystic fibrosis

    by Daniel J. Smith, Kerenaftali Klein, Gunter Hartel, Claire E. Wainwright, Scott C. Bell, Gregory J. Anderson, David W. Reid


  • Open Access

    Anomalies in T Cell Function Are Associated With Individuals at Risk of Mycobacterium abscessus Complex Infection

    by Viviana P. Lutzky, Champa N. Ratnatunga, Daniel J. Smith, Andreas Kupz, Denise L. Doolan, David W. Reid, Rachel M. Thomson, Scott C. Bell, John J. Miles

    The increasing global incidence and prevalence of non-tuberculous mycobacteria (NTM) infection is of growing concern. New evidence of person-to-person transmission of multidrug-resistant NTM adds to the global concern. The reason why certain individuals are at risk of NTM infections is unknown. Using high definition flow cytometry, we studied the immune profiles of two groups that are at risk of Mycobacterium abscessus complex infection and matched controls. The first group was cystic fibrosis (CF) patients and the second group was elderly individuals. CF individuals with active M. abscessus complex infection or a history of M. abscessus complex infection exhibited a unique surface T cell phenotype with a marked global deficiency in TNFα production during mitogen stimulation. Importantly, immune-based signatures were identified that appeared to predict at baseline the subset of CF individuals who were at risk of M. abscessus complex infection. In contrast, elderly individuals with M. abscessus complex infection exhibited a separate T cell phenotype underlined by the presence of exhaustion markers and dysregulation in type 1 cytokine release during mitogen stimulation. Collectively, these data suggest an association between T cell signatures and individuals at risk of M. abscessus complex infection, however, validation of these immune anomalies as robust biomarkers will require analysis on larger patient cohorts.


  • Open Access

    Phenotyping bronchiectasis: is it all about sputum and infection?

    by Daniel J. Smith

    New subclassification of bronchiectasis patients may help inform targeted therapy http://ow.ly/XT5ez